Anti-tumour effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines.
Open Vet J
; 14(5): 1259-1268, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38938437
ABSTRACT
Background:
Canine prostatic carcinoma (cPC) is a urogenital tumour with a poor prognosis, for which no effective treatment has been established. Recently, it has been shown that human epidermal growth factor receptor type 2 (HER2) is overexpressed in cPC cells; however, the efficacy of HER2-targeted therapy remains unclear.Aim:
Investigate the anti-tumour effect of lapatinib on HER2-positive cPC cell lines.Methods:
Two cell lines (muPC and bePC) were established from two dogs with cPC and the effects of lapatinib treatment on cell proliferation, apoptosis, and HER2 downstream signalling were investigated. Furthermore, muPC was used to generate tumour-bearing mice, and the anti-tumour effects of lapatinib were examined in vivo.Results:
Lapatinib treatment inhibited the proliferation and phosphorylation of Erk1/2 and Akt, which are downstream signals of HER2. Furthermore, the TUNEL assay showed that lapatinib induced apoptosis in both cell lines. The muPC-engrafted nude mouse model showed that lapatinib significantly inhibited tumour growth and increased the area of necrotic tumour tissue compared to the vehicle-treated groups.Conclusion:
Lapatinib exerts anti-tumour effects on cPC cells by inhibiting HER-2 signalling.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Receptor, ErbB-2
/
Dog Diseases
/
Lapatinib
/
Mice, Nude
/
Antineoplastic Agents
Limits:
Animals
Language:
En
Journal:
Open Vet J
Year:
2024
Document type:
Article